Peter Hau

Franz Josef Strauss Allee 11
Regensburg, BY 93053, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 165 publications

Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF).

Safety and feasibility of tumor treating fields initiated before and during radiotherapy for newly diagnosed glioblastoma: results from the Arm A feasibility cohort of a phase I/II trial (PriCoTTF).

Journal: BMC cancer

Published: June 18, 2026

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY).

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2026

ClpP activation in high-risk medulloblastoma: ONC206 as a potent inducer of the integrated stress response and mitochondrial damage for a broader therapeutic window.

ClpP activation in high-risk medulloblastoma: ONC206 as a potent inducer of the integrated stress response and mitochondrial damage for a broader therapeutic window.

Journal: Neuro-oncology

Published: April 16, 2026

Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis.

Lomustine with or without procarbazine in recurrent glioblastoma-A propensity score matching analysis.

Journal: Neuro-oncology advances

Published: February 20, 2026

Survival of primary brain tumor patients according to treatment in certified oncologic centers.

Survival of primary brain tumor patients according to treatment in certified oncologic centers.

Journal: Cancer treatment and research communications

Published: December 15, 2025

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Preventive strategies against brain metastases: current state of the art and future directions.

Preventive strategies against brain metastases: current state of the art and future directions.

Journal: Neurological research and practice

Published: December 01, 2025

Lactic acid promotes an MDSC-like phenotype via HIF1α stabilization with impact on prognosis in renal cell carcinoma.

Lactic acid promotes an MDSC-like phenotype via HIF1α stabilization with impact on prognosis in renal cell carcinoma.

Journal: Cancer letters

Published: November 18, 2025

MRI-defined patterns of infiltration and outcome in patients with glioblastoma.

MRI-defined patterns of infiltration and outcome in patients with glioblastoma.

Journal: Neuro-oncology advances

Published: August 22, 2025

Palliative care interventions and outcome in patients with glioblastoma - a retrospective, single-center study.

Palliative care interventions and outcome in patients with glioblastoma - a retrospective, single-center study.

Journal: BMC palliative care

Published: August 16, 2025

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: July 13, 2025

European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project.

European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research project.

Journal: Neuro-oncology practice

Published: June 13, 2025

Showing 1-12 of 165

Last Updated: 09/26/2026